Loading clinical trials...
Loading clinical trials...
Study 22003, "An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders(ASD)" currently is evaluating th...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Seaside Therapeutics, Inc.
NCT07076264 · Autism Spectrum Disorders
NCT06848959 · Cerebral Palsy, Mental Retardation, and more
NCT01031407 · Asperger's Disorder, Mental Retardation, and more
NCT04737707 · Autism Spectrum Disorders
NCT02747056 · Autism Spectrum Disorders
Southwest Autism Research & Resource Center
Phoenix, Arizona
University of California-Los Angeles Neuropsychiatric Institute
Los Angeles, California
Yale Child Study Center
New Haven, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions